288 related articles for article (PubMed ID: 23673814)
1. Tetrahydrofurofuran-type lignans inhibit breast cancer-mediated bone destruction by blocking the vicious cycle between cancer cells, osteoblasts and osteoclasts.
Jun AY; Kim HJ; Park KK; Son KH; Lee DH; Woo MH; Chung WY
Invest New Drugs; 2014 Feb; 32(1):1-13. PubMed ID: 23673814
[TBL] [Abstract][Full Text] [Related]
2. 15-deoxy-δ12,14-prostaglandin j2 inhibits osteolytic breast cancer bone metastasis and estrogen deficiency-induced bone loss.
Kim KR; Kim HJ; Lee SK; Ma GT; Park KK; Chung WY
PLoS One; 2015; 10(4):e0122764. PubMed ID: 25859665
[TBL] [Abstract][Full Text] [Related]
3. Betulinic acid, a bioactive pentacyclic triterpenoid, inhibits skeletal-related events induced by breast cancer bone metastases and treatment.
Park SY; Kim HJ; Kim KR; Lee SK; Lee CK; Park KK; Chung WY
Toxicol Appl Pharmacol; 2014 Mar; 275(2):152-62. PubMed ID: 24463094
[TBL] [Abstract][Full Text] [Related]
4. The cross-talk between osteoclasts and osteoblasts in response to strontium treatment: involvement of osteoprotegerin.
Peng S; Liu XS; Huang S; Li Z; Pan H; Zhen W; Luk KD; Guo XE; Lu WW
Bone; 2011 Dec; 49(6):1290-8. PubMed ID: 21925296
[TBL] [Abstract][Full Text] [Related]
5. The inhibitory effect of roasted licorice extract on human metastatic breast cancer cell-induced bone destruction.
Lee SK; Park KK; Park JH; Lim SS; Chung WY
Phytother Res; 2013 Dec; 27(12):1776-83. PubMed ID: 23401151
[TBL] [Abstract][Full Text] [Related]
6. Arctigenin suppresses receptor activator of nuclear factor κB ligand (RANKL)-mediated osteoclast differentiation in bone marrow-derived macrophages.
Kim AR; Kim HS; Lee JM; Choi JH; Kim SN; Kim DK; Kim JH; Mun SH; Kim JW; Jeon HS; Kim YM; Choi WS
Eur J Pharmacol; 2012 May; 682(1-3):29-36. PubMed ID: 22387094
[TBL] [Abstract][Full Text] [Related]
7. Involvement of cell-cell and cell-matrix interactions in bone destruction induced by metastatic MDA-MB-231 human breast cancer cells in nude mice.
Nakamura H; Hiraga T; Ninomiya T; Hosoya A; Fujisaki N; Yoneda T; Ozawa H
J Bone Miner Metab; 2008; 26(6):642-7. PubMed ID: 18979165
[TBL] [Abstract][Full Text] [Related]
8. RANK ligand is a prerequisite for cancer-associated osteolytic lesions.
Kitazawa S; Kitazawa R
J Pathol; 2002 Oct; 198(2):228-36. PubMed ID: 12237883
[TBL] [Abstract][Full Text] [Related]
9. TGF-beta promotion of Gli2-induced expression of parathyroid hormone-related protein, an important osteolytic factor in bone metastasis, is independent of canonical Hedgehog signaling.
Johnson RW; Nguyen MP; Padalecki SS; Grubbs BG; Merkel AR; Oyajobi BO; Matrisian LM; Mundy GR; Sterling JA
Cancer Res; 2011 Feb; 71(3):822-31. PubMed ID: 21189326
[TBL] [Abstract][Full Text] [Related]
10. Expression of osteoprotegerin and RANK ligand in breast cancer bone metastasis.
Park HR; Min SK; Cho HD; Kim DH; Shin HS; Park YE
J Korean Med Sci; 2003 Aug; 18(4):541-6. PubMed ID: 12923331
[TBL] [Abstract][Full Text] [Related]
11. A Selective FGFR inhibitor AZD4547 suppresses RANKL/M-CSF/OPG-dependent ostoclastogenesis and breast cancer growth in the metastatic bone microenvironment.
Kang J; Choi YJ; Seo BY; Jo U; Park SI; Kim YH; Park KH
Sci Rep; 2019 Jun; 9(1):8726. PubMed ID: 31217507
[TBL] [Abstract][Full Text] [Related]
12. RANKL inhibition combined with tamoxifen treatment increases anti-tumor efficacy and prevents tumor-induced bone destruction in an estrogen receptor-positive breast cancer bone metastasis model.
Canon J; Bryant R; Roudier M; Branstetter DG; Dougall WC
Breast Cancer Res Treat; 2012 Oct; 135(3):771-80. PubMed ID: 22926264
[TBL] [Abstract][Full Text] [Related]
13. Gut-derived serotonin induced by depression promotes breast cancer bone metastasis through the RUNX2/PTHrP/RANKL pathway in mice.
Zong JC; Wang X; Zhou X; Wang C; Chen L; Yin LJ; He BC; Deng ZL
Oncol Rep; 2016 Feb; 35(2):739-48. PubMed ID: 26573960
[TBL] [Abstract][Full Text] [Related]
14. Parathyroid hormone-related protein and bone metastases.
Guise TA
Cancer; 1997 Oct; 80(8 Suppl):1572-80. PubMed ID: 9362424
[TBL] [Abstract][Full Text] [Related]
15. Breast cancer cells interact with osteoblasts to support osteoclast formation.
Thomas RJ; Guise TA; Yin JJ; Elliott J; Horwood NJ; Martin TJ; Gillespie MT
Endocrinology; 1999 Oct; 140(10):4451-8. PubMed ID: 10499498
[TBL] [Abstract][Full Text] [Related]
16. Plumbagin inhibits breast tumor bone metastasis and osteolysis by modulating the tumor-bone microenvironment.
Li Z; Xiao J; Wu X; Li W; Yang Z; Xie J; Xu L; Cai X; Lin Z; Guo W; Luo J; Liu M
Curr Mol Med; 2012 Sep; 12(8):967-81. PubMed ID: 22574935
[TBL] [Abstract][Full Text] [Related]
17. Coptisine inhibits RANKL-induced NF-κB phosphorylation in osteoclast precursors and suppresses function through the regulation of RANKL and OPG gene expression in osteoblastic cells.
Lee JW; Iwahashi A; Hasegawa S; Yonezawa T; Jeon WB; Cha BY; Nagai K; Woo JT
J Nat Med; 2012 Jan; 66(1):8-16. PubMed ID: 21656335
[TBL] [Abstract][Full Text] [Related]
18. Inhibition of RANKL blocks skeletal tumor progression and improves survival in a mouse model of breast cancer bone metastasis.
Canon JR; Roudier M; Bryant R; Morony S; Stolina M; Kostenuik PJ; Dougall WC
Clin Exp Metastasis; 2008; 25(2):119-29. PubMed ID: 18064531
[TBL] [Abstract][Full Text] [Related]
19. Heparin enhances osteoclastic bone resorption by inhibiting osteoprotegerin activity.
Irie A; Takami M; Kubo H; Sekino-Suzuki N; Kasahara K; Sanai Y
Bone; 2007 Aug; 41(2):165-74. PubMed ID: 17560185
[TBL] [Abstract][Full Text] [Related]
20. Anti-tumor effect in human breast cancer by TAE226, a dual inhibitor for FAK and IGF-IR in vitro and in vivo.
Kurio N; Shimo T; Fukazawa T; Takaoka M; Okui T; Hassan NM; Honami T; Hatakeyama S; Ikeda M; Naomoto Y; Sasaki A
Exp Cell Res; 2011 May; 317(8):1134-46. PubMed ID: 21338601
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
